ORPHA:1529
Craniofacial-deafness-hand syndrome
Also known as: CDHS · Craniofacial-hearing loss-hand syndrome · Sommer-Young-Wee-Frye syndrome
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
258
76.2th percentile
Trials
0
Interventional, condition-specific
Researchers
1,234
Distinct authors in sample
Gene link
PAX3
Definitive
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare multiple anomalies syndrome characterized by facial dysmorphism (including flat facial profile normal calvarium, hypertelorism, small downslanting palpebral fissures with an antimongoloid slant, hypoplastic nose with button tip and slitlike nares, and small, pursed mouth), profound sensorineural hearing loss/deafness and hand anomalies such as ulnar deviations and contractures of the hand.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0007395
- MeSH:C536453
- OMIM:122880
- UMLS:C1852510
Additional Mondo synonyms (1)
craniofacial-deafness-hand syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — PAX3
- LiteraturePresent
258 matched papers (172 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (PAX3).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
258
258 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
258 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
172 in the last 10 years · medium confidence · 76.2th percentile (publications denominator)
Phrase hits: 258 · MeSH hits: 0
Who's working on it?
1,234
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Barateau L5 papers · 2026
Department of Neurology, Sleep-Wake Disorders Center, Gui-de-Chauliac Hospital, CHU, Montpellier, France.
Papers in Europe PMC - 02Dauvilliers Y5 papers · 2026
Department of Neurology, Sleep-Wake Disorders Center, Gui-de-Chauliac Hospital, CHU, Montpellier, France.
Papers in Europe PMC - 03Pizza F3 papers · 2026
Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.
Papers in Europe PMC - 04Plazzi G3 papers · 2026
IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Papers in Europe PMC - 05Ruano R3 papers · 2024
Department of Obstetrics and Gynecology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Papers in Europe PMC - 06Wang J3 papers · 2026
Department of Ophthalmology, Dezhou People's Hospital, Dezhou 253000, Shandong Province, China.
Papers in Europe PMC - 07Araujo Júnior E2 papers · 2024
Department of Obstetrics, Paulista School of Medicine - Federal University of São Paulo (EPM-UNIFESP), São Paulo-SP, Brazil.
Papers in Europe PMC - 08Biscarini F2 papers · 2025
Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.
Papers in Europe PMC - 09Brunelli L2 papers · 2023
University of Utah School of Medicine, Salt Lake City, Utah.
Papers in Europe PMC - 10Buhl DL2 papers · 2026
Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
medium confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Craniofacial-deafness-hand syndrome" OR "Craniofacial-hearing loss-hand syndrome" OR "Sommer-Young-Wee-Frye syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Craniofacial-deafness-hand syndrome" OR "Craniofacial-hearing loss-hand syndrome" OR "Sommer-Young-Wee-Frye syndrome" OR "PAX3"
Recall-expansion terms: PAX3
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: CDHS
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T17:39:11.671Z